Oryzon Genomics SA
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain. Show More...
-
Website https://www.oryzon.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 2.70 EUR
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share EUR 0.23 -0.04 -0.2 -0.16 -0.03 -0.08 -0.08 Dividends EUR Payout Ratio % * Shares Mil 28.0 27.0 28.0 33.0 38.0 45.0 45.0 Book Value Per Share * EUR 0.87 1.06 0.88 1.38 1.33 Free Cash Flow Per Share * EUR -0.14 -0.26 -0.25 -0.21 Return on Assets % 25.52 -2.97 -12.04 -9.38 -1.83 -4.99 -5.11 Financial Leverage (Average) 1.88 1.48 2.19 1.77 1.49 1.31 1.29 Return on Equity % 47.87 -4.78 -21.65 -18.18 -2.96 -6.94 -7.0 Return on Invested Capital % 40.76 -2.2 -12.32 -9.26 -1.01 -4.71 -5.1 Interest Coverage 10.84 -0.46 -4.85 -5.43 -3.62 -4.93 -6.69 Current Ratio 2.52 4.28 3.75 4.15 3.42 3.58 3.09 Quick Ratio 2.46 4.18 3.68 4.09 3.32 3.47 2.91 Debt/Equity 0.21 0.11 0.66 0.38 0.16 0.06 0.05